Physician profile
Melissa Schmidt
NPI 1144992934
$1,957.52
in general payments reported to CMS, 2019-2025
24 companies · $690 in 2025
The $690 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $498 · 2024: $611 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $296.69 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $270.85 | 2023-2025 | Xtandi |
| Myriad Genetic Laboratories, INC. | $265.47 | 2023-2025 | Myrisk, Prolaris |
| Sun Pharmaceutical Industries INC. | $203.88 | 2025 | |
| Pfizer INC. | $100.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.51 | 2023-2025 | |
| Blue Earth Diagnostics | $95.94 | 2024-2025 | Posluma |
| Janssen Biotech, INC. | $76.33 | 2024-2025 | Erleada |
| Merck Sharp & Dohme LLC | $67.58 | 2023-2025 | Lynparza, Keytruda |
| Abbvie INC. | $62.39 | 2022-2024 | |
| Coloplast Corp | $58.24 | 2023-2025 | Speedicath |
| Urogen Pharma, INC. | $55.13 | 2024-2025 | |
| Immunitybio, INC. | $43.81 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $35.84 | 2022-2023 | Provenge |
| Astrazeneca Pharmaceuticals LP | $34.06 | 2022-2024 | Lynparza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.60 | 2025 | |
| Tolmar, INC. | $26.86 | 2024 | |
| Progenics Pharmaceuticals, INC. | $25.22 | 2025 | |
| Sumitomo Pharma America, INC. | $22.41 | 2025 | Orgovyx |
| Olympus America INC. | $21.12 | 2024 | Itind System |
| Laborie Medical Technologies Corp. | $20.65 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Ferring Pharmaceuticals INC. | $18.69 | 2025 | Adstiladrin |
| Axonics, INC. | $13.75 | 2024 | Bulkamid, Axonics |
| Ambu INC. | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.